

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
26 February 2004 (26.02.2004)

PCT

(10) International Publication Number  
WO 2004/016621 A1

(51) International Patent Classification<sup>7</sup>: C07D 498/04,  
A61K 31/424, A61P 25/24, 25/16, 25/18 // (C07D 498/04,  
311:00, 261:00)

Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse  
(BE).

(21) International Application Number:  
PCT/EP2003/050374

(74) Common Representative: JANSSEN PHARMACEU-  
TICA N.V.; Turnhoutseweg 30, B-2340 Beerse (BE).

(22) International Filing Date: 12 August 2003 (12.08.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,  
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,  
UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
02078322.1 12 August 2002 (12.08.2002) EP

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*):  
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turn-  
houtseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): ANDRÉS-GIL,  
José, Ignacio [ES/ES]; c/o Janssen Cilag S.A., Edificio  
Johnson & Johnson, Paseo de las Doce Estrellas 5-7,  
Campo de las Naciones, 28042 Madrid (ES). BARTO-  
LOMÉ-NEBREDÁ, José, Manuel [ES/ES]; c/o  
Janssen Cilag S.A., Edificio Johnson & Johnson, Paseo  
de las Doce Estrellas 5-7, Campo de las Naciones, 28042  
Madrid (ES). ALVAREZ-ESCOBAR, Rosa, Maria  
[ES/ES]; c/o Janssen Cilag S.A., Edificio Johnson &  
Johnson, Paseo de las Doce Estrellas 5-7, Campo de las  
Naciones, 28042 Madrid (ES). BAKKER, Margaretha,  
Henrica, Maria [NL/DE]; Hachnleinerstrasse 16A,  
64665 Alsbach-Hachnlein (DE). MEGENS, Antonius,  
Adrianus, Hendrikus, Petrus [NL/BE]; c/o Janssen

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a  
patent (Rule 4.17(ii)) for all designations
- as to the applicant's entitlement to claim the priority of the  
earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: C-SUBSTITUTED TRICYCLIC ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTI-DEPRESSANTS



(I)

(57) Abstract: The invention  
concerns substituted tricyclic  
isoxazoline derivatives according  
to Formula (I), the pharmaceutically  
acceptable acid or base addition  
salts thereof, the stereochemically  
isomeric forms thereof and the  
N-oxide form thereof, more in  
particular tricyclic dihydrobenzopy-  
ranoisoxazoline, dihydroquinolinoisoxazoline, dihydronaphthalenoisoxazoline and dihydrobenzothiopyranoisoxazoline derivatives

substituted on the phenylpart of the tricyclic moiety with at least one radical that is attached to the phenyl radical by a carbon-carbon bond as well as processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine, in particular for treating depression, anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders including anorexia nervosa and bulimia, wherein all variables are defined in Claim 1. (I) The compounds have surprisingly been shown to have selective serotonin (5-HT) reuptake inhibitor activity in combination with additional  $\alpha_2$ -adrenoceptor antagonist activity and show a strong anti-depressant and/or anxiolytic activity and/or antipsychotic and/or a body weight control activity without being sedative. Also, in view of their selective serotonin (5-HT) reuptake inhibitor as well as  $\alpha_2$ -adrenoceptor antagonist activity, compounds according to the invention are also suitable for treatment and/or prophylaxis in diseases where either one of the activities alone or the combination of said activities may be of therapeutic use.